Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

21.0%

50 terminated/withdrawn out of 238 trials

Success Rate

75.8%

-10.7% vs industry average

Late-Stage Pipeline

19%

45 trials in Phase 3/4

Results Transparency

51%

80 of 157 completed trials have results

Key Signals

1 recruiting80 with results39 terminated11 withdrawn

Enrollment Performance

Analytics

Phase 2

125(60.7%)

Phase 3

45(21.8%)

Phase 1

25(12.1%)

N/A

11(5.3%)

206Total

Phase 2(125)

Phase 3(45)

Phase 1(25)

N/A(11)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (238)

Showing 20 of 238 trials

NCT03740165Phase 3Completed

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

Role: collaborator

NCT04498117Phase 3Active Not Recruiting

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Role: collaborator

NCT02655016Phase 3Active Not Recruiting

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Role: collaborator

NCT07109414Phase 2Active Not Recruiting

Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)

Role: collaborator

NCT04393285Phase 2Active Not Recruiting

Abemaciclib and Letrozole to Treat Endometrial Cancer

Role: lead

NCT03673124Phase 2Active Not Recruiting

Ribociclib and Letrozole Treatment in Ovarian Cancer

Role: lead

NCT04209855Phase 3Completed

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

Role: collaborator

NCT01979393Phase 2Completed

IRCI Gynae Sarcomas, High Grade Uterine Sarcoma

Role: collaborator

NCT03522246Phase 3Active Not Recruiting

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Role: collaborator

NCT04634877Phase 3Active Not Recruiting

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

Role: collaborator

NCT05257408Phase 3Active Not Recruiting

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Role: collaborator

NCT01445275Withdrawn

Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199

Role: lead

NCT01344837Completed

Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer

Role: lead

NCT01198171Completed

Racial and Genetic Biomarkers of Response in Tissue Samples From Patients With Endometrial Cancer

Role: lead

NCT01164735Completed

Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer